Clinical Trial

Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this multicenter, prospective, open-label, controlled, randomized trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving clinical cardiovascular outcomes in patients with acute coronary syndrome.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-10.
Status change: Not Yet Recruiting → Recruiting 2024-05-21
Trial Details
NCT Number NCT06365502
Lead Sponsor Harbin Medical University
Collaborators: Shanghai Shenqi Medical Technology Co., Ltd
Conditions Acute Coronary Syndrome (ACS)
Enrollment 1,860 participants
Start Date 2024-04-16
Primary Completion 2027-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-22